ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

ABVC vs CELU // FORWARD P/E MULTIPLE

ABVC BioPharma Inc. (NASDAQ) VS. Celularity Inc. (Class A) (NASDAQ) • 15-METRIC TALLY: ABVC 2 — CELU 0
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ABVC VS. CELU) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC ABVC CELU SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — 24.40% — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -35.00% 0.00 TIE /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield -10.76% — — TIE /fcf-yield <GO>
Operating Margin — -60.00% — TIE /operating-margins <GO>
Net Profit Margin — -60.00% — TIE /net-margins <GO>
Revenue Growth (YoY) — -51.00% — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 1/9 1/9 0.00 TIE /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 52.8 38.4 +14.40 ABVC /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple ACTIVE — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $27.8M $27.6M $201.9K ABVC /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR ABVC REV CELU REV ABVC GROSS % CELU GROSS % ABVC FCF CELU FCF
FY 2025 $0 $26.6M — 24.4% -$3.0M -$13.3M
FY 2024 $509.6K $54.2M 98.0% 72.4% -$1.8M -$6.6M
FY 2023 $152.4K $22.8M — — -$4.2M -$38.7M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ABVC // BETA —
CELU // BETA —